Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product

Use of low doses of enteric-coated or buffered aspirin carries a three-fold increase in the risk of major UGIB. The assumption that these formulations are less harmful than plain aspirin may be mistaken.